Specimens must be submitted using NantHealth collection kits. If kits are needed please contact 1.844.MY.OMICS for assistance.
Detailed instructions for specimen collection and submission are provided in each collection kit. You may also refer to our Specimen Selection Tips sheet for more information.
NantHealth strives to ensure a seamless experience when undergoing molecular profiling. We are committed to supporting patients and physicians by streamlining the insurance billing process and limiting the financial burden wherever possible.
For answers to many common billing questions, please download the Billing FAQ. For more information, NantHealth’s billing specialists are available to answer inquiries before, during, and after testing. To speak with a billing specialist, please contact us at 1.844.MY.OMICS.
Financial Assistance through the NantAccess Program
Secondary Germline Screening
What is secondary germline screening?
The DNA and/or RNA sequence data generated during molecular analysis of cancer can also be evaluated for secondary findings that may have medical utility for you and your patient. Performed in addition to the principal testing of the cancer specimen, this secondary analysis offered by NantHealth looks for genetic variants that are present not only in cancer cells, but also in noncancerous cells within the body. These more widely distributed genetic abnormalities are referred to as germline abnormalities since they are likely to be present in reproductive tissue often referred to as the germline. Secondary screening is optional, and patients will have the opportunity to opt in or opt out while completing the NantHealth Patient Informed Consent.
What genes are evaluated in the secondary germline screening?
NantHealth offers secondary screening for a select set of cancer predisposition genes. This list, available for download below, includes a number of genes that are recommended by the American College of Medical Genetics (ACMG) and are compatible with our genetic analytic processes.
What is the clinical significance of secondary findings?
The presence of germline genetic abnormalities in cancer predisposition genes can lead to an increased risk of particular types of cancers and other medical conditions. Knowing that an individual has a germline abnormality in a cancer predisposition gene could be beneficial as screening for future cancers and/or specialized therapies may be available. Since these types of abnormalities can be inherited, there also is a chance that other family members related by blood could also carry these genetic abnormalities. The results of secondary screening performed by NantHealth should be discussed with the physician, who may recommend consultation with a medical geneticist. (At this time, NantHealth does not provide genetic counseling.)
What are the limitations of the secondary germline screening?
The testing procedure employed for this screening only looks for a very specific class of genetic abnormalities that are predicted to disrupt the function of these genes. This screening test does not comprehensively evaluate these genes for all types of alterations that may have clinical consequences, thus there could be additional genetic abnormalities in any of the genes regardless of the test result. Furthermore, not all genes that increase the risk of cancer are included in this test.
What does secondary screening cost?
The test is run at no additional cost.
How should a patient decide whether to opt in to secondary germline screening?
If a patient has questions about whether to opt in or out for secondary germline screening, the patient should discuss with his or her physician.
How does a patient opt in to secondary screening, and how do they receive the results?
Patients have the opportunity to opt in/out of secondary germline testing while completing the NantHealth Patient Informed Consent. If the patient indicates that s/he wishes to have this test performed, the test will be performed in parallel with the other genomic testing of your cancer and normal tissue samples, and the results will be included in the clinical report containing the cancer genomics test results. This test will not affect the time required to generate the clinical report.
Specimen Selection Tips
NantAccess Program Financial Assistance Application